以色列Rosetta Genomics 
以色列Rosetta Genomics，是一家小RNA（microRNA）公司，已经与哥伦比亚大学签约共同研发先进的肿瘤诊断试剂。按照合同，哥伦比亚大学医学中心将利用其临床实验室改进修订案(CLIA)认可的实验室作为Rosetta Genomics的实践基地，以检测该公司诊断试剂对那些来源不明肿瘤确定的可能性。Rosetta Genomic公司正研发多种基于microRNA的诊断试剂。

Rosetta Genomics is a leading molecular diagnostics company advancing molecular tests based on its proprietary microRNAs, and platform technologies. Following the launch of five cancer tests since the beginning of 2009, the Company is now working to develop additional tests in the cancer realm and in other fields.
Rosetta Genomics is a leading developer of microRNA-based diagnostic tests and therapeutic tools. MicroRNAs (miRNAs) are a recently discovered group of short (21–23 nucleotides in length), non-coding genes which regulate the expression of other genes. MicroRNAs have also been shown to have varying expression levels across various pathological conditions, and offer a new class of highly sensitive and tissue specific biomarkers. MicroRNA-based diagnostics may offer physicians and patients an objective tool to accurately identify cancer, predict outcomes and help guide treatment.

Platform Technologies

Backed by a strong IP portfolio, Rosetta Genomics’ scientists have developed proprietary platform technologies for the identification, extraction, quantification, and analysis of microRNAs from a wide range of sample types. These technologies enable the identification and advancement of multiple diagnostic projects addressing critical unmet needs in cancer, women’s health and other indications.

Development Engine

Based on our strong IP position which provides us access to hundreds of potential microRNAs biomarkers, our proprietary technologies, and our extensive network of collaborations, Rosetta Genomics has put in place a powerful development engine which can rapidly advance a wide range of microRNA-based tests.

Advancing Cutting Edge Molecular Diagnostics

Rosetta Genomics’ proprietary technologies enable the development of a wide range of diagnostic tests for cancer and women’s health indications. Rosetta genomics believes that utilizing microRNAs as biomarkers in the development of next generation molecular diagnostics, presents several advantages over other currently used methods:

While many currently available cancer tests are largely qualitative and subjective, measuring microRNA expression levels in tissue samples offers quantitative, objective diagnosis.

Rosetta Genomics’ proprietary technologies enable microRNAs to be profiled with high sensitivity and specificity.

MicroRNAs are stable markers in many body fluids and tissue samples, making them an ideal platform for molecular diagnostics.

MicroRNAs have been found to be stable in Formalin Fixed Paraffin Embedded (FFPE) samples. FFPE samples, which are kept at room temperature, are the most widely used method for preserving tumor tissue. This will allow physicians to send samples for microRNA profiling via regular mail, without the need for temperature control.

MicroRNA-based Therapeutics

We seek to establish relationships with leading pharmaceutical companies and research institutions to develop microRNA-based products. In 2006, we joined forces with Isis Pharmaceuticals Inc. to develop a drug for liver cancer. We have identified several microRNA targets, that, when inhibited, lead to a decrease in liver cancer cell growth in in vivo studies1.